After decades of procedures and millions upon millions of implant recipients, the FDA has formalized procedures that, among other things, now require patient notification of the potential risks and complications that come with breast augmentation surgery.
The move comes after several cases of breast implant-associated large cell lymphoma were reported in primarily European markets. Initially thought to be tied to the textured implants used mostly by European doctors, ...
continue reading...The Mayo Clinic and the American Society of Plastic Surgeons have both published information about a rare cancer with possible ties to breast implants as concerns continue to grow over breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL.
Initially, BIA-ALCL was thought to be a mostly European concern as the condition was generally associated with women who had received textured rather than smoothly surfaced ...
continue reading...The death toll formally attributed to breast implant-associated anaplastic large cell lymphoma now stands at 36, although it could be higher. Three new fatalities have occurred within the same six months and just weeks before the implants implicated in the deaths were set to be recalled.
The implants in question were made by Allergan prior to its acquisition by AbbVie. The Biocell textured ...
continue reading...After millions upon millions of procedures performed over the span of several decades, the safety of the implants used in breast augmentation and reconstructive surgeries have been thrust to the forefront of thought for both the medical community and the women who underwent the operations. For most women exploring the idea of implants in the late-20th to early-21st centuries, concerns over the procedure were limited to ...
Approximately 30 lawsuits filed against healthcare goods manufacturer Allergan will be consolidated into a single multidistrict litigation. Plaintiffs in the lawsuits made the request to the Judicial Panel on Multidistrict Litigation over their claims that the company’s breast implant products are responsible for their development or potential development of breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL.
The extraordinarily rare cancer first became ...
continue reading...The long-term safety of breast implants; a topic widely thought to have been resolved over the decades, is receiving renewed interest from medical communities around the world and is now on the radar of the U.S. Food and Drug Administration. What started as concern over a type of cancer predominantly tied to textured breast implants has led to new questions being ...
